Dermatologic Therapy

Papers
(The H4-Index of Dermatologic Therapy is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Oral manifestations ofCOVID‐19 disease: A review article163
COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study70
Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID ‐19 pandemic53
The impact of air pollution on skin and related disorders: A comprehensive review51
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis50
Telogen effluvium associated with COVID‐19 infection46
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study45
Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study42
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study42
Cutaneous adverse reactions after COVID‐19 vaccines in a cohort of 2740 Italian subjects: An observational study42
COVID‐19 and exacerbation of dermatological diseases: A review of the available literature37
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting36
COVID ‐19 vaccine‐induced urticarial vasculitis36
Evaluating hyaluronic acid dermal fillers: A critique of current characterization methods35
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study35
Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence34
Efficacy of resveratrol in the wound healing process by reducing oxidative stress and promoting fibroblast cell proliferation and migration33
Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report33
Onset of vitiligo in a psoriasis patient on ixekizumab32
Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study32
Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options32
Telogen effluvium related to post severe Sars‐Cov‐2 infection: Clinical aspects and our management experience32
Psoriasis flare after influenza vaccination in Covid‐19 era: A report of four cases from a single center32
Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases31
Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine31
Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising31
Possible association between IgA vasculitis and COVID ‐1931
JAK‐inhibitors for dermatomyositis: A concise literature review30
Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?30
Systematic review of platelet‐rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability30
Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors30
“Covid arm”: Abnormal side effect after Moderna COVID ‐19 vaccine30
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders30
0.02162504196167